Knight study on multiple myeloma supports new standard of treatment

A new study, published in the New England Journal of Medicine, found that 63 percent of multiple myeloma patients have a reduced risk of disease progression or death if treated with lenalidomide (Revlimid®) following a stem cell transplant. The study was co-authored by Richard Mariarz, MD, medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the Knight Cancer Institute.

Read the OHSU News Release to learn more.

Bookmark and Share

Comments are closed.

About the Author

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Read more

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.

Categories

Archives